NovoCure (NVCR) reported a Q3 loss Wednesday of $0.28 per diluted share, narrower than a loss of $0.46 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.33.
Net revenue for the quarter ended Sept. 30 was $155.1 million, up from $127.3 million a year earlier.
Analysts surveyed by Capital IQ expected $144 million.
Price: 16.53, Change: -0.09, Percent Change: -0.54